-
Ethnicity and the need for correction of biochemical and ultrasound markers of chromosomal anomalies in the first trimester: a study of Oriental, Asian and Afro-Caribbean populations.
Spencer K, Heath V, El-Sheikhah A, Ong CY, Nicolaides KH.
Prenat Diagn 2005;25:365-9. -
First-Trimester Screening for Chromosomal Abnormalities.
Nicolaides KH.
Semin Perinatol 2005;29:190-4. -
Maternal serum biochemistry at 11-13(+6) weeks in relation to the presence or absence of the fetal nasal bone on ultrasonography in chromosomally abnormal fetuses: an updated analysis of integrated ultrasound and biochemical screening.
Cicero S, Spencer K, Avgidou K, Faiola S, Nicolaides KH.
Prenat Diagn 2005;25:977-83. -
The impact of correcting for smoking status when screening for chromosomal anomalies using maternal serum biochemistry and fetal nuchal translucency thickness in the first trimester of pregnancy.
Spencer K, Bindra R, Cacho AM, Nicolaides KH.
Prenat Diagn 2004;24:169-73. -
Nuchal translucency and other first-trimester sonographic markers of chromosomal abnormalities.
Nicolaides KH.
Am J Obstet Gynecol 2004;191:45-67. -
Glycosaminoglycans and proteoglycans in the skin of aneuploid fetuses with increased nuchal translucency.
von Kaisenberg CS, Prols F, Nicolaides KH, Maass N, Meinhold-Heerlein I, Brand-Saberi B.
Hum Reprod 2003;18:2544-61. -
Delta-NT or NT MoM: which is the most appropriate method for calculating accurate patient-specific risks for trisomy 21 in the first trimester?
Spencer K, Bindra R, Nix AB, Heath V, Nicolaides KH.
Ultrasound Obstet Gynecol 2003;22:142-8. -
Screening for chromosomal abnormalities in the first trimester using ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years prospective experience.
Spencer K, Spencer CE, Power M, Dawson C, Nicolaides KH.
BJOG 2003;110:281-6. -
Sonographic markers of fetal aneuploidy: a review.
Cicero S, Sacchini C, Rembouskos G, Nicolaides KH.
Placenta 2003;24:S88-98. -
Absent nasal bone at 11-14 weeks of gestation and chromosomal defects.
Cicero S, Longo D, Rembouskos G, Sacchini C, Nicolaides KH.
Ultrasound Obstet Gynecol 2003;22:31-5. -
The transcription factor Prox1 is a marker for lymphatic endothelial cells in normal and diseased human tissues.
Wilting J, Papoutsi M, Christ B, Nicolaides KH, von Kaisenberg CS, Borges J, Stark GB, Alitalo K, Tomarev SI, Niemeyer C, Rossler J.
FASEB J 2002;16:1271-3. -
A first trimester trisomy 13/trisomy 18 risk algorithm combining fetal nuchal translucency thickness, maternal serum free beta-hCG and PAPP-A.
Spencer K, Nicolaides KH.
Prenat Diagn 2002;22:877-9. -
Increased fetal nuchal translucency at 11-14 weeks.
Nicolaides KH, Heath V, Cicero S.
Prenat Diagn 2002;22:308-15. -
One-stop clinic for assessment of risk of chromosomal defects at 12 weeks of gestation.
Nicolaides KH, Bindra R, Heath V, Cicero S.
J Matern Fetal Neonatal Med 2002;12:9-18. -
Fetal nasal bone length in chromosomally normal and abnormal fetuses at 11-14 weeks of gestation.
Cicero S, Bindra R, Rembouskos G, Tripsanas C, Nicolaides KH.
J Matern Fetal Neonatal Med 2002;11:400-2. -
Screening for chromosomal defects by fetal nuchal translucency at 11 to 14 weeks.
Bindra R, Heath V, Nicolaides KH.
Clin Obstet Gynecol 2002;45:661-70. -
Measurement of fetal nuchal translucency thickness by three-dimensional ultrasound.
Paul C, Krampl E, Skentou C, Jurkovic D, Nicolaides KH.
Ultrasound Obstet Gynecol 2001;18:481-4. -
The influence of parity and gravidity on first trimester markers of chromosomal abnormality.
Spencer K, Ong CYT, Liao AWJ, Papademetriou D, Nicolaides KH.
Prenat Diagn 2000;20:792-4. -
One stop clinic for assessment of risk for fetal anomalies: a report of the first year of prospective screening for chromosomal anomalies in the first trimester.
Spencer K, Spencer CE, Power M, Moakes A, Nicolaides KH.
BJOG 2000;107:1271-5. -
The 11-14 week scan.
Nicolaides KH, Heath V, Liao AW.
Baillieres Best Pract Res Clin Obstet Gynaecol 2000;14:581-94.